The FLEX VESSEL PREP™ Treatment of

STENOSED AV ACCESS

DYNAMIC ENGAGEMENT

Expansion at ~1 atm of radial force, combined with a retrograde pullback motion, enables continuous engagement of the dynamic treatment element along entire length of the stenosis

MICRO-INCISIONS

Precise surgical blades create controlled-depth, continuous micro-incisions in fibrotic and neointimal hyperplasia stenosis

NEOINTIMAL HYPERPLASIA MODIFICATION

Creating longitudinal micro-incisions in the stenosis releases the circumferential tension to enable luminal gain with improved vessel compliance, reduced vessel trauma and complications while potentially enhancing and facilitating drug pathways

The FLEX VESSEL PREP™ Treatment of

STENOSED AV ACCESS

DYNAMIC ENGAGEMENT

Expansion at ~1 atm of radial force, combined with a retrograde pullback motion, enables continuous engagement of the dynamic treatment element along entire length of the stenosis

MICRO-INCISIONS

Precise surgical blades create controlled-depth, continuous micro-incisions in fibrotic and neointimal hyperplasia stenosis

NEOINTIMAL HYPERPLASIA MODIFICATION

Creating longitudinal micro-incisions in the stenosis releases the circumferential tension to enable luminal gain with improved vessel compliance, reduced vessel trauma and complications while potentially enhancing and facilitating drug pathways

AV Case Example

MID AV SEGMENT STENOSIS

Pre-FLEX Baseline

Post-FLEX

FLEX + Balloon

AV Case Example

MID AV SEGMENT STENOSIS

Pre-FLEX Baseline

Post-FLEX

FLEX + Balloon

WHY FLEX FIRST?

Optimize vascular access of AVF/AVG with full-length micro-incisions in AV stenosis:

  • Improves lesion compliance reducing the need for high pressure balloons
  • Consistent, long, micro-incisions safely prepare vessels with less barotrauma for further therapy
  • Create pathways to potentially enhance and facilitate drug access to stenosed vessels when utilizing DCB’s

SAFE

  • Predictable, controlled-depth micro-incisions .010”
  • Minimizes risk of severe complications and vessel trauma

EASY-TO-USE

  • Simple design treats long, or short lesions
  • Short learning curve with minimal user variation
  • One size fits most stenosis

COST EFFICIENT

  • No capital equipment – only one or two SKUs to stock (shaft length)
  • Quick over-the-wire set-up, and use
  • Optimizing DCB may reduce repeat interventions

WHY FLEX FIRST?

Optimize vascular access of AVF/AVG with full-length micro-incisions in AV stenosis:

  • Improves lesion compliance and may reduce the need for high pressure balloons
  • Consistent, long, micro-incisions safely prepare vessels with less barotrauma for further therapy
  • Create pathways to potentially enhance and facilitate drug access to stenosed vessels when utilizing DCB’s

SAFE

Predictable, controlled-depth micro-incisions .010”

Minimizes risk of severe complications and vessel trauma

EASY-TO-USE

Simple design treats long, or short lesions

Short learning curve with minimal user variation

One size fits most stenosis

COST EFFICIENT

No capital equipment – only one or two SKUs to stock (shaft length)

Quick over-the-wire set-up, and use

Optimizing DCB may reduce repeat interventions

Safe, Easy, and Effective

AV ACCESS TREATMENT

  • 6Fr, .014” or .018” guidewire (OTW)
  • Reinforced braided shaft for consistent deliverability and torque performance
  • 2mm atraumatic tip for enhanced trackability and crossing profile
  • Two working lengths – 40 cm and 120 cm (US and OUS)
  • For use in the femoral and popliteal arteries and AV fistulas and grafts

Safe, Easy, and Effective

AV ACCESS TREATMENT

  • 6Fr, .014” or .018” guidewire (OTW)
  • Reinforced braided shaft for consistent deliverability and torque performance
  • 2mm atraumatic tip for enhanced trackability and crossing profile
  • Two working lengths – 40 cm and 120 cm (US and OUS)
  • For use in the femoral and popliteal arteries and AV fistulas and grafts

RESISTANT STENOSIS + RESTENOSIS IN AVF/AVG

Does Vessel Prep Make a Difference?

AVAFLEX Study 6 Months Results

John Ross, MD.
Medical Director – The Regional Medical Center, SC

Watch the full slide presentation →

RESISTANT STENOSIS + RESTENOSIS IN AVF/AVG

Does Vessel Prep Make a Difference?

AVAFLEX Study 6 Months Results

John Ross, MD.
Medical Director – The Regional Medical Center, SC

CONTACT US


Headquarters

2800 Campus Drive, Suite 50

Plymouth, MN 55441, USA

Phone: 763 951 0280

Fax: 419 558 4171

Email: info@venturemedgroup.com

Authorized EU Representative

MedNet, EC-REP GmbH

Borkstraße 10, 48163 Münster, Germany

+49 251 322660

CONTACT US


Headquarters

2800 Campus Drive, Suite 50
Plymouth, MN 55441, USA
Phone: 763 951 0280
Fax: 419 558 4171
Email: info@venturemedgroup.com

Authorized EU Representative

MedNet, EC-REP GmbH
Borkstraße 10, 48163 Münster, Germany
+49 251 322660

VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.

VentureMed Group, Inc. is a member of Medical Alley

VentureMed Group, Inc. develops and markets innovative endovascular medical devices to solve unmet medical needs in the treatment of PAD and stenoses of AV fistulas and grafts.

VentureMed Group, Inc. is a member of Medical Alley